GRAS Path Draws Interest As NDI Alternative, But Carries Challenges

In the wake of FDA’s draft guidance on NDI notifications, more companies reevaluate the status of their ingredients before going to market. The GRAS for use in foods process is a clear – but rigorous – alternative pathway.

As manufacturers and ingredient suppliers look to assimilate FDA’s draft guidance on new dietary ingredient notifications into product development, the appeal of generally recognized as safe status as an alternative is growing.

But the path toward an affirmation of GRAS for use in foods comes with its own obstacles, industry stakeholders say.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from HBW Insight

Kennedy Appears Ill-Informed On Major Pharma Priorities, Creating Unique Lobbying Dynamics

 

Health and Human Services secretary made incorrect statements about the status of key industry priorities at a recent House hearing, which actually may be a good thing for drug sponsors.

Lupin Goes For Growth With Indian Consumer Health Spin-Off

 
• By 

With annual sales approaching $20m, LupinLife Consumer Healthcare has ambitious growth plans for the Indian OTC market.

L’Oréal Plans Purchase Of Color Wow Brand

 

L’Oréal has signed an agreement to acquire the Color Wow professional styling brand for an undisclosed price.